Phase 1 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who weigh at least 40 kg (approximately 88 pounds).
• People who have been confirmed by laboratory testing to have T-cell acute lymphoblastic leukaemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL) that has come back or stopped responding to treatment.
• People aged 12 to 30 years old.
• People who are able to carry out a reasonable level of daily activity, as measured by standard medical scoring tools — a score of 60 or above on the relevant scale for their age (confirm with trial site).
• People whose heart is pumping adequately, as shown by specific heart function measurements (confirm with trial site).
• People whose liver is functioning well enough, based on blood test results, though some exceptions may apply if abnormal results are caused by the underlying disease (confirm with trial site).
• People whose kidneys are functioning adequately, based on a calculated measure of kidney filtration — unless any reduced function is related to the disease itself (confirm with trial site).
• People who have waited a sufficient amount of time since their last cancer treatment before starting this trial — generally at least 14 days, or five half-lives of the previous treatment, whichever is shorter. In some cases, certain short-term medications may be permitted beforehand (confirm with trial site).
• People receiving treatment to prevent or manage cancer in the central nervous system (brain and spinal cord) may still be considered.
• People who have previously received one or more of the study drugs, as long as they were not previously given in the same combination used in this trial.
• People with a history of hepatitis B who have an undetectable viral load while on suppressive therapy.
• People with a history of hepatitis C who have been successfully treated and cured, or who are currently being treated and have an undetectable viral load.
• People who have had brain involvement from cancer that has been treated, with follow-up scans showing no signs of the cancer actively growing.
• People with known heart disease or a history of treatment with medications that can affect the heart, who are assessed as being in a stable enough cardiac condition (Class 2B or better on a standard heart function scale) as determined by the treating doctor.
• People who are able to use an approved method of contraception for the duration of the trial and for a set period afterwards. This applies to women who could become pregnant and to men. Accepted methods include hormonal contraception, intrauterine devices (IUDs), surgical sterilisation, vasectomy (in a partner), implantable or injectable contraceptives, and condoms with spermicide. Complete abstinence for the full duration of the trial is also accepted. Periodic abstinence, the rhythm method, and withdrawal are not accepted (confirm with trial site for full details).
• Men enrolled in the trial must agree to use adequate contraception before, during, and for 4 months after completing the trial.

Who may not be able to join:

• People who have another serious uncontrolled medical condition, significant abnormal lab results, or a psychiatric illness that could put them at unacceptable risk from the study treatment.
• People who are currently receiving other anti-cancer treatments not specified in this trial's protocol.
• People who are taking other chemotherapy or anti-leukaemia medications during the trial, except for a small number of permitted exceptions such as certain medications given directly into the spinal fluid, short-term use of specific drugs for rapidly progressing disease, or approved supportive care treatments (confirm with trial site).
• People who have a severe digestive or metabolic condition that could interfere with the absorption of medications taken by mouth.
• People with severe, uncontrolled nerve damage (peripheral neuropathy) that significantly affects movement or sensation.
• People who are currently being treated for a second active cancer.
• People with a currently active hepatitis B, hepatitis C, or HIV infection. Note: testing is not required unless there is a known or suspected history.
• People who are pregnant or breastfeeding.
• People who have an active infection that is not under control.
• People whose medical history, current condition, or test results might, in the treating doctor's opinion, affect the study results or make full participation unsafe or not in the person's best interest.
• People who have had allergic reactions to drugs with a similar makeup to venetoclax, dexamethasone, bortezomib, or daratumumab — the medications used in this trial.

Important: Always verify eligibility with the trial site directly before applying.